GSK1572932A ( Non-Small Cell Lung Cancer)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Opportunity and Unmet Need 32
6.1 Overview 32
6.2 Improved Overall Survival and Less Toxicity 33
6.3 Treatments for Patients with Acquired TKI Resistance 34
6.4 Better Treatment Options for Squamous Patients 35
6.5 Preventing Relapse or Recurrence 35
6.6 More Efficacious Second-Line Therapies 36
6.7 Increased Availability of Mutation Testing 36
6.8 More Cost-Effective Therapies 37
6.9 Unmet Needs Gap Analysis 38
7 Pipeline Assessment 42
7.1 Overview 42
7.2 Promising Drugs in Clinical Development 42
8 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 46
8.1 Overview 46
8.2 Efficacy 47
8.3 Safety 47
8.4 Dosing and Formulation 48
8.5 Potential Clinical Positioning 48
8.6 Potential Commercial Positioning 48
8.7 Pricing and Reimbursement 49
8.8 SWOT Analysis 49
8.9 Forecast 50
9 Appendix 51
9.1 Bibliography 51
9.2 Abbreviations 55
9.3 Methodology 58
9.4 Forecasting Methodology 58
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 58
9.4.2 Percent Drug-treated Patients 59
9.4.3 General Pricing Assumptions 59
9.4.4 Individual Drug Assumptions 62
9.4.5 Generic Erosion 62
9.4.6 Pricing of Pipeline Agents 62
9.5 Physicians and Specialists Included in This Study 63
9.6 Survey of Prescribing Physicians 64
9.7 About the Authors 65
9.7.1 Author 65
9.7.2 Epidemiologist 65
9.7.3 Global Head of Healthcare 66
9.8 About GlobalData 67
9.9 Disclaimer 67